Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to Strong-Buy at Cantor Fitzgerald

Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by equities research analysts at Cantor Fitzgerald to a “strong-buy” rating in a research note issued to investors on Thursday,Zacks.com reports.

Other equities analysts also recently issued reports about the company. Wall Street Zen upgraded shares of Inhibikase Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Inhibikase Therapeutics in a report on Wednesday, October 8th. Lifesci Capital raised Inhibikase Therapeutics to a “strong-buy” rating in a report on Monday, December 1st. Finally, Zacks Research upgraded Inhibikase Therapeutics to a “hold” rating in a report on Tuesday, December 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Inhibikase Therapeutics presently has a consensus rating of “Moderate Buy”.

Inhibikase Therapeutics Stock Up 1.0%

NASDAQ:IKT opened at $1.54 on Thursday. The stock has a 50-day simple moving average of $1.55. The stock has a market cap of $115.78 million, a P/E ratio of -3.95 and a beta of 0.88. Inhibikase Therapeutics has a 1-year low of $1.33 and a 1-year high of $4.20.

Inhibikase Therapeutics (NASDAQ:IKT) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.13) EPS for the quarter.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.